Drug Combination Details
| General Information of the Combination (ID: C29048) | |||||
|---|---|---|---|---|---|
| Name | Silibinin NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | ||
|
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [2] | |||
|
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [3] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MPIP3 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| MH-3924A | CVCL_5799 | Rat hepatocellular carcinoma | Rattus norvegicus | |||
| In-vivo Model | An orthotopic rat model of HCC was used, in which subcutaneously injected Morris hepatoma (MH)-3924A cells (5x106) in syngeneic ACI rats. | |||||
| Experimental
Result(s) |
Silibinin strongly synergized with doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis of HEPG2 cells. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MPIP3 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
| In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
| LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | SLC2A1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | LoVo | CVCL_0399 | Colon adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Silybin counteracts doxorubicin resistance by inhibiting GLUT1 expression. | |||||
